NCT07314164 2026-02-27
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Ipsen
Recruiting
Clinical Trials
24 trialsNCT03691064 2025-12-23
SALUS
Advanced Accelerator Applications
Active not recruiting
NCT05844332 2025-12-22
LUTATHERA Injection General Use Result Survey
Novartis
Completed
NCT02270567 2025-11-13
RegisterNET
Wren Laboratories LLC
Enrolling by invitation
NCT04727723 2025-10-03
REAL-LU
Advanced Accelerator Applications
Active not recruiting
NCT06358001 2025-09-22
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
Completed
NCT06253897 2024-12-24
BackSOM
Ipsen
Completed
NCT04649580 2024-12-17
PREF-NET
Ipsen
Completed
NCT03223428 2024-07-24
RELAX
TerSera Therapeutics LLC
Completed
NCT02282059 2024-06-20
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Pfizer
Completed
NCT05922579 2024-02-29
A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET
Ipsen
Terminated
NCT05967481 2023-08-01
Evaluation of Study Experiences of Neuroendocrine Tumor Patients
Power Life Sciences Inc.
Not yet recruiting
NCT05816720 2023-04-18
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
Completed
NCT02630654 2021-12-07
EXPLAIN
Ipsen
Completed
NCT01234168 2020-11-05
SYMNET
Ipsen
Completed
NCT03895463 2020-11-05
NETways
Ipsen
Withdrawn
NCT03562091 2020-08-28
OPERA
Ipsen
Completed
NCT02730104 2020-06-26
Community-based Neuroendocrine Tumor (NET) Research Study
Ipsen
Completed
NCT03112694 2020-06-02
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Ipsen
Completed
NCT01840449 2019-01-14
SOPRANo
Ipsen
Completed
NCT00747786 2019-01-07
Non Interventional Post Marketing Programme in Neuroendocrine Tumours
Ipsen
Completed
NCT02788578 2018-12-21
PRELUDE
Ipsen
Terminated
NCT03017690 2018-12-21
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Ipsen
Completed
NCT03220087 2018-12-21
RECOSY
Ipsen
Completed